By Nanobiotix
Disrupting drug design and development to unleash the power of innovative therapies No matter the disease being treated, drug bioavailability — the extent to which a drug enters systemic circulation and accesses the targeted tissues — is critical for therapeutic efficacy.1 However, in order for a drug to reach the maximally effective concentration at the target tissue, it must overcome a significant biological hurdle: the patient’s own body. The liver is dedicated to removing compounds from the blood, including many drugs. Due to this process, many promising therapeutic candidates that are administered directly to the blood by IV have poor or suboptimal bioavailability, leading to low or no accumulation in target tissues and potentially high off-target toxicity.2 Consequently, while many of these drugs show potential in the lab, many are not viable in the clinic. To address this challenge, we developed the Curadigm Nanoprimer Platform. The Curadigm Nanoprimer is designed to temporarily increase the bioavailability of subsequently administered therapies while minimizing the risk of off-target effects. This first-in-class concept could unleash the power of innovative therapeutics such as RNA/DNA-based drugs, gene therapies, oncolytic viruses, and nanomedicines by removing a major biological barrier to their success in the clinic. Moreover, solving the liver clearance problem could allow approved drugs to work more efficiently and further improve outcomes for patients. Curadigm Nanoprimer Platform: Enabling liver bypass to create better outcomes Comprised of a precisely engineered lipid-based nanoparticle, our Nanoprimer is designed to temporarily occupy the liver pathways responsible for therapeutic clearance, in order to enable a given drug to concentrate in target tissues while minimizing the risk of harm to the patient’s liver. Curadigm Nanoprimer Platform key advantages 01 Temporarily increases systemic bioavailability 02 Uncouples therapeutic blood bioavailability & delivery, allowing optimized drug function 03 Does not use drugs or biologics to occupy the liver and does not elicit an immune response Maximize therapeutic potential We seek to partner with companies who share our interest in overcoming the hurdles of poor bioavailability and/or hepatotoxicity that limit the clinical utility of otherwise promising therapies. Our Nanoprimer platform can be leveraged across multiple intravenously administered therapeutic classes and indications Therapeutic Classes Nanomedicines Encapsulating Small Molecules Nucleic Acid (RNA & DNA) Genome Editing Materials (CRISPR-Cas-9) Drug Conjugates Oncolytic Viruses Therapy Areas Oncology Rare Diseases Infectious diseases Central nervous system diseases
